CHECKMATE-017

Regimen

Experimental
nivolumab
Control
docetaxel

Population

Pretreated advanced squamous NSCLC

Key finding

mOS 9.2 vs 6.0 mo, HR 0.59 (0.44-0.79); first PD-1 mAb approved in NSCLC

Source: PMID 26028407

Timeline

    Guideline citations

    • NCCN NSCLC Version 5.2026 (p.180)